Physician profile
Hamza Minhas
NPI 1558792788
$6,939.47
in general payments reported to CMS, 2019-2025
59 companies · $45.56 in 2025
The $45.56 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $352 · 2021: $1,290 · 2022: $2,101 · 2023: $1,873 · 2024: $493 · 2025: $45.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Education: $66.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.09 |
| Education | $66.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $757.06 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $460.35 | 2019-2024 | Enhertu, Calquence, Lynparza |
| Eisai INC. | $408.75 | 2019-2024 | |
| Janssen Biotech, INC. | $406.88 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $366.23 | 2019-2024 | Opdivo, Pomalyst |
| Merck Sharp & Dohme LLC | $307.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $306.08 | 2019-2024 | Enhertu, Injectafer |
| Genentech USA, INC. | $289.60 | 2019-2023 | Tecentriq |
| Amgen INC. | $283.70 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| Seagen INC. | $274.44 | 2020-2023 | Adcetris |
| Pfizer INC. | $263.23 | 2019-2024 | |
| Incyte Corporation | $250.94 | 2021-2024 | Jakafi, Monjuvi |
| Celgene Corporation | $205.92 | 2022-2023 | Reblozyl |
| Lilly USA, LLC | $193.74 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Genzyme Corporation | $165.19 | 2019-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.